FDA approved Pfizer-BioNTech’s XFG-adapted COMIRNATY formula for adults 65 and older and high-risk people aged 5 to 64 years.
News|Slideshows|May 17, 2019
Combating the Rise in STIs
Author(s)Veronica Hackethal, MD
Two recent studies presented at the Conference on Retroviruses and Opportunistic Infections highlight novel approaches to combat rising STI rates.
Advertisement
Advertisement
Related to this article
A Vaccine Integrity Project review found influenza, COVID-19, and RSV immunizations continue to protect against severe illness, hospitalization, and death.
FDA approved bictegravir/lenacapavir for adults with suppressed HIV-1 and no known or suspected component resistance.
FDA expands dolutegravir dispersible tablets to children with HIV-1 weighing at least 2 kg, including eligible term newborns.
Pre-existing antibodies to common microbes predicted COVID-19 vaccine response strength in healthy and immunosuppressed adults.
The organizations challenge a presidential executive order narrowing routine childhood vaccine recommendations and urging vaccines to be given separately.
FDA acceptance starts review of clesrovimab for second-season RSV prevention in high-risk children younger than 2 years.
Advertisement
Advertisement
Trending on Patient Care Online
1
Combating Prostate Cancer Misconceptions in Primary Care: An Expert Discussion
2
ASH Raises Ferritin Thresholds for Diagnosing Iron Deficiency
3
Endocrine Society Obesity Statement Calls for Goals Beyond Weight Loss
4
The Shift From Off-Label Use to On-Label Agitation Therapy
5